Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
65295-69-4 | 2,6-Difluorophenyl isocyanate | AA003G1S | MFCD00001998
72955-86-3 | 2-[2-(Methylthio)phenoxy]ethylamine | AA003G5X | MFCD17171366
700-63-0 | 2-Amino-2-phenylacetamide | AA003G9V | MFCD00025498
722549-98-6 | 2-Amino-4-morpholinopyridine | AA003GCX | MFCD09991750
5154-00-7 | 2-Amino-6-hydroxypyridine | AA003GFR | MFCD00039717
51901-85-0 | 2-BROMO-1,3,2-BENZODIOXABOROLE | AA003GJ3 | MFCD00013341
343262-51-1 | 2-Bromo-5-(methylsulfonyl)pyridine | AA003GMA | MFCD04974509
91983-14-1 | 2-Bromomethylphenylboronic acid | AA003GPD | MFCD01318941
33234-36-5 | 2-Chloro-3-methoxybenzoic acid | AA003GT0 | MFCD07784399
1060804-57-0 | 2-Chloro-5-hydroxyisonicotinic acid | AA003GW8 | MFCD13189124